2018 美国CDC建议:每周1次异烟肼-利福喷丁疗法治疗潜伏结核分枝杆菌感染(更新)

2018-08-31 美国疾病控制与预防中心 MMWR Morb Mortal Wkly Rep. 2018 Jun 29;67(25):723-

MMWR Morb Mortal Wkly Rep. 2018 Jun 29;67(25):723-726.

中文标题:

2018 美国CDC建议:每周1次异烟肼-利福喷丁疗法治疗潜伏结核分枝杆菌感染(更新)

英文标题:

Update of Recommendations for Use of Once-Weekly Isoniazid-Rifapentine Regimen to Treat Latent Mycobacterium tuberculosis Infection.

发布日期:

2018-08-31

简要介绍:

2018年7月,美国疾病控制与预防中心(CDC)更新了每周1次异烟肼-利福喷丁疗法治疗潜伏结核分枝杆菌感染建议,本文是对2011年CDC短期异烟肼-利福喷治疗建议的更新。 

拓展指南:结核相关指南:

相关资料下载:
[AttachmentFileName(sort=100, fileName=2018 美国CDC建议:每周1次异烟肼-利福喷丁疗法治疗潜伏结核分枝杆菌感染(更新))] GetToolGuiderByIdResponse(projectId=1, id=dbcc11c00163a1c1, title=2018 美国CDC建议:每周1次异烟肼-利福喷丁疗法治疗潜伏结核分枝杆菌感染(更新), enTitle=Update of Recommendations for Use of Once-Weekly Isoniazid-Rifapentine Regimen to Treat Latent Mycobacterium tuberculosis Infection., guiderFrom=MMWR Morb Mortal Wkly Rep. 2018 Jun 29;67(25):723-, authorId=null, author=, summary=MMWR Morb Mortal Wkly Rep. 2018 Jun 29;67(25):723-726. , cover=, journalId=null, articlesId=null, associationId=109, associationName=美国疾病控制与预防中心, associationIntro=致力于保护健康和促进预防和控制疾病,设有疾病预防控制中心咨询委员会&mdash;&mdash;联邦咨询委员会,提供卫生监测系统的监测和防止疾病暴发(包括生物恐怖主义),实施疾病预防战略,并保持国家卫生统计与各国和其他合。提供流行病学统计等数据。, copyright=0, guiderPublishedTime=Fri Aug 31 22:59:31 CST 2018, originalUrl=, linkOutUrl=, content=<div>2018年7月,美国疾病控制与预防中心(CDC)更新了每周1次异烟肼-利福喷丁疗法治疗潜伏结核分枝杆菌感染建议,本文是对2011年CDC短期异烟肼-利福喷治疗建议的更新。 </div> <div><br> </div>拓展指南:<strong>与<font color=red>结核</font>相关指南:</strong><br><ul><li><a href="http://www.medsci.cn/guideline/show_article.do?id=993081c001620117" title="2018 比利时指南:HIV感染患者潜伏性结核筛查" target=_blank>2018 比利时指南:HIV感染患者潜伏性结核筛查</a></li> <li><a href="http://www.medsci.cn/guideline/show_article.do?id=bc0a91c001611961" title="肺结核影像学及分级诊断专家共识" target=_blank>肺结核影像学及分级诊断专家共识</a></li> <li><a href="http://www.medsci.cn/guideline/show_article.do?id=85e721c00160a8c4" title="抗结核药物超说明书用法专家共识" target=_blank>抗结核药物超说明书用法专家共识</a></li> <li><a href="http://www.medsci.cn/guideline/show_article.do?id=70c221c0015980d4" title="2018 WHO指南: 异烟肼耐药结核病的治疗" target=_blank>2018 WHO指南: 异烟肼耐药结核病的治疗</a></li> <li><a href="http://www.medsci.cn/guideline/show_article.do?id=e4a881c0015ae218" title="利奈唑胺抗结核治疗专家共识" target=_blank>利奈唑胺抗结核治疗专家共识</a></li> 更多信息请点击:<a href="http://www.medsci.cn/guideline/list.do?q=%E7%BB%93%E6%A0%B8" target=_blank>有关结核更多指南</a></ul>, tagList=[TagDto(tagId=9368, tagName=异烟肼), TagDto(tagId=79966, tagName=利福喷丁疗法), TagDto(tagId=79967, tagName=潜伏结核分枝杆菌感染)], categoryList=[CategoryDto(categoryId=9, categoryName=感染, tenant=100), CategoryDto(categoryId=21100, categoryName=达仁堂循证e学界, tenant=100)], articleKeywordId=null, articleKeyword=null, articleKeywordNum=null, guiderKeywordId=null, guiderKeyword=null, guiderKeywordNum=null, haveAttachments=1, attachmentList=null, guiderType=0, guiderArea=其他, guiderLanguage=0, guiderRegion=1, opened=0, paymentType=null, paymentAmount=10, recommend=0, recommendEndTime=null, sticky=0, stickyEndTime=null, allHits=6543, appHits=154, showAppHits=6, pcHits=4846, showPcHits=2350, likes=163, shares=3, comments=2, approvalStatus=1, publishedTime=Fri Aug 31 22:58:17 CST 2018, publishedTimeString=2018-08-31, pcVisible=1, appVisible=1, editorId=2020535, editor=qiushida2, waterMark=0, formatted=0, memberCards=[], isPrivilege=0, deleted=0, version=1, createdBy=null, createdName=qiushida2, createdTime=Fri Aug 31 22:58:17 CST 2018, updatedBy=null, updatedName=null, updatedTime=Wed Jan 03 06:53:28 CST 2024, courseDetails=[], otherVersionGuiders=[], isGuiderMember=false, ipAttribution=, attachmentFileNameList=[AttachmentFileName(sort=100, fileName=2018 美国CDC建议:每周1次异烟肼-利福喷丁疗法治疗潜伏结核分枝杆菌感染(更新))])
2018 美国CDC建议:每周1次异烟肼-利福喷丁疗法治疗潜伏结核分枝杆菌感染(更新)
下载请点击:
评论区 (2)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=342051, encodeId=ad1634205190, content=谢谢分享,学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=93, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6Nx0VGA4QMDzOP8oAgnV4h51EjSfehJ9QxyiaSmw8PB56BhY8KXFSxHCibXrzcy4abrzSibXQPxJ9kzrLcJyhhB8a/0, createdBy=1d3b1672603, createdName=明月清辉, createdTime=Sat Sep 01 06:26:06 CST 2018, time=2018-09-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=342040, encodeId=9b15342040da, content=学习了,谢谢分享, beContent=null, objectType=guider, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c592194322, createdName=1209e435m98(暂无昵称), createdTime=Sat Sep 01 01:37:39 CST 2018, time=2018-09-01, status=1, ipAttribution=)]
    2018-09-01 明月清辉

    谢谢分享,学习了

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=342051, encodeId=ad1634205190, content=谢谢分享,学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=93, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6Nx0VGA4QMDzOP8oAgnV4h51EjSfehJ9QxyiaSmw8PB56BhY8KXFSxHCibXrzcy4abrzSibXQPxJ9kzrLcJyhhB8a/0, createdBy=1d3b1672603, createdName=明月清辉, createdTime=Sat Sep 01 06:26:06 CST 2018, time=2018-09-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=342040, encodeId=9b15342040da, content=学习了,谢谢分享, beContent=null, objectType=guider, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c592194322, createdName=1209e435m98(暂无昵称), createdTime=Sat Sep 01 01:37:39 CST 2018, time=2018-09-01, status=1, ipAttribution=)]
    2018-09-01 1209e435m98(暂无昵称)

    学习了,谢谢分享

    0